little work has been done on its possible functions and regulation. In relation to this latter aspect, it has been reported that the enzyme activity is enhanced by acute administration of ethanol, tyrosine (Badawy et al., 1980b) or cortisol (Laboritt & Thuret, 1977) . On the other hand, Mandel & Aunis (1974) reported (without providing supporting data) that cortisol does not enhance the enzyme activity. In view of these latter two contradictory reports, we have performed in the present paper a detailed investigation of the effects of cortisol on rat brain tyrosine aminotransferase activity and found that it is enhanced.
Materials and methods
Locally bred male Wistar rats (150-170g) were maintained on cube diet 41 B (Oxoid, Basingstoke, Hants., U.K.) and water and were killed by decapitation between 14:00 and 14:30h. The brains were rapidly removed (within 20 s of the death of the animals), immersed in liquid N2 for 3 min and stored at -200C for up to 24h before analysis. Badawy et al. (1980b) Chemicals were intraperitoneally administered. Cortisol acetate (2.5-50mg/kg body wt.) was dissolved in dimethylformamide and appropriate control rats received an equal volume (1 ml/kg body wt.) of this solvent. Actinomycin D (0.7 mg/kg body wt.) or cycloheximide (10mg/kg body wt.) was dissolved in 0.9% (w/v) NaCl and control rats received an equal volume (2 ml/kg body wt.) of 0.9% NaCl.
Brain tyrosine -aminotransferase activity was determined in whole homogenates by the method (Badawy et al., 1980a) used for the assay of the hepatic enzyme, but with some modifications. These were: (1) the incorporation into the 6.4ml incubation mixture of 0.6ml of a 16% (v/v) solution of Triton X-100 (in: the 0.2M-potassium phosphate buffer, pH 7.3); (2) pre-incubation of all components of the reaction mixture (except the 2-oxoglutarate solution) for 15min at 37°C; (3) performing the incubation at 370C for 45 min instead of the shorter time intervals used with the hepatic enzyme. Whole brain homogenates were prepared by homogenizing the frozen tissue in 4vol. of 0.14M-KCl/2.5mm-KOH (at 0-20C) for 1 min by using an Ultra-Turrax homogenizer. Portions (0.1 ml each) of this homogenate were then assayed.
The half-life of brain tyrosine aminotransferase was determined by the method previously described (Badawy et al., 1980a) for that of the hepatic enzyme. Statistical analysis of results was performed by using Student's t test.
Results and discussion
The time course of the effects of administration of a 20mg/kg body wt. dose of cortisol acetate on rat brain tyrosine aminotransferase activity is shown in Fig. 1 (Fig. 2) .
No significant changes in enzyme activities were observed with doses of up to 5 mg/kg body wt. The 7.5mg/kg body wt. dose caused a 22% increase (P<0.001) in the holoenzyme activity. Activities of both the holoenzyme and total enzyme were then increased in a dose-dependent fashion, with the 30mg/kg body wt. dose causing the maximum -increases (99% and 95% respectively; P<0.001). These results therefore demonstrate the ability of administered cortisol to enhance rat brain tyrosine aminotransferase activity.
The cortisol induction of liver tyrosine aminotransferase has been much studied and it is now well established that the hormone does not stabilize this hepatic enzyme, but that it enhances its synthesis at the mRNA level (see e.g. Nickol et al., 1978) . To find out if cortisol acts similarly on the activity of the brain enzyme, further experiments were performed. The results in Table 1 show that the enhancement of both the holoenyzme and total enzyme activities observed at S h after cortisol administration (75% and 59% respectively; P <0.001) was abolished by Table 1 . Prevention by actinomycin D and cycloheximide of the enhancement of rat brain tyrosine aminotransferase activity by cortisol Rats were killed at 5h after intraperitoneal administration of cortisol acetate (20mg/kg body wt.) or an equal volume (1 ml/kg body wt.) of the solvent dimethylformamide. The animals were also pretreated, 30min before the above two agents, with actinomycin D (0.7 mg/kg body wt.), cycloheximide (0mg/kg body wt.) or an equal volume (2 ml/kg body wt.) of 0.9% (w/v) NaCl. The enzyme activity was determined as described in the Materials and methods section either in the absence (holoenzyme activity) or in the presence (total enzyme activity) of added (40pM) pyridoxal 5'-phosphate. The values given are means ± S.E.M. for each group of four rats. The holoenzyme and total enzyme activities in cortisol-treated rats are compared with those in control (dimethylformamide-treated) animals and the significance of differences is indicated as follows: *P < 0.001.
Tyrosine pretreatment of rats with either actinomycin D or cycloheximide. Neither agent exerted any significant effects (P>0.10) on the basal enzyme activities in control (dimethylformamide-treated) rats. It may therefore be concluded that the cortisol-induced enhancement of rat brain tyrosine aminotransferase activity is sensitive to blockade by inhibitors of transcription and translation, and this is consistent with the hormone enhancing the mRNA-dependent synthesis of the enzyme. To find out if cortisol alters the half-life of brain tyrosine aminotransferase, cycloheximide (10mg/kg body wt.) was administered at 5h after rats had already received an injection of cortisol acetate (20mg/kg body wt.) or an equal volume of dimethylformamide and the enzyme activities were again determined at 1 and 2 h after the cycloheximide injection. The total enzyme activity (in umol of 4-hydroxyphenylpyruvate formed/h per g wet wt. of brain + S.E.M. for each group of four rats) at 0, 1 and 2 h after cycloheximide administration to control (dimethylformamide-pretreated) rats was 3.42 + 0.14, 2.76 + 0.11 and 2.06 + 0.05 respectively. The corresponding total enzyme activity of cortisol-pretreated rats was 5.88 + 0.12, 4.57 + 0.14 and 3.58+0.10 respectively at 0, 1 and 2h after cycloheximide administration. A plot of each of these two sets of data on semi-logarithmic paper revealed that the half-life of the total enzyme in control rats (2.63h) was not much altered (2.53h) by cortisol. Similar experiments and plots were also performed in relation to the holoenzyme and the half-life of this was found to be 2.61 and 2.64 h in control and cortisol-pretreated rats respectively. These results therefore suggest that cortisol does not stabilize rat brain tyrosine aminotransferase. The half-lives of the basal enzyme (that in rats treated with 0.9% NaCl 3 h before cycloheximide) have previously been shown (Badawy et al., 1980b) to be 2.38 and 2.49 h for the holoenzyme and total enzyme respectively.
In conclusion, the findings of the present paper have demonstrated the ability of administered cortisol to enhance rat brain tyrosine aminotransferase activity by a mechanism excluding stabilization of the enzyme, but possibly involving an increase in its synthesis. These findings and those (Badawy et al., 1980b) demonstrating the ability of administered tyrosine to enhance this cerebral enzyme suggest that brain tyrosine aminotransferase may be subject to regulation by glucocortisoids and by its tyrosine substrate. Further work is, however, required to examine these possibilities.
